SEC Form 4 · accession 0001140361-15-021768
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — SVP, Chief Commercial Of
Period of report
May 26, 2015
Accepted (ET)
May 26, 2015 · 7:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 26, 2015 | S | 1,625 | $126.5523 | D | 39,245 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed May 11, 2015.
- F2The price in column 4 is a weighted average price. The price actually received ranged from $125.64 to $128.47. The reporting person shall provide to the issuer, and security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.